World Pharma News Digest - 14.05.2012

3 views
Skip to first unread message

Ruslan David

unread,
May 14, 2012, 4:45:55 AM5/14/12
to worldph...@googlegroups.com
Vitamin K2: New hope for Parkinson's patients?
‎Neuroscientist Patrik Verstreken, associated with VIB and KU Leuven, succeeded in undoing the effect of one of the genetic defects that leads to Parkinson's using vitamin K2. His discovery gives hope to Parkinson's patients.
Read more...
http://www.worldpharmanews.com/research/2073-vitamin-k2-new-hope-for-parkinsons-patients
 
FDA issues alert on potential dangers of unproven treatment for multiple sclerosis
‎The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called "liberation therapy" or the "liberation procedure" to treat chronic cerebrospinal venous insufficiency (CCSVI).
Read more...
http://www.worldpharmanews.com/fda/2072-fda-issues-alert-on-potential-dangers-of-unproven-treatment-for-multiple-sclerosis
 
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
‎GlaxoSmithKline plc (LSE: GSK) today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$13.00 per share in cash.
Read more...
http://www.worldpharmanews.com/gsk/2071-gsk-commences-tender-offer-to-acquire-human-genome-sciences-for-us-1300-per-share-in-cash
 
Cancer Support Community launches national program to assist patients with cancer
‎The Cancer Support Community (CSC) and the Amgen Foundation, today announced the launch of Open to Options", a program designed to bridge the communications gap between physicians and patients and inspire patient confidence in making treatment decisions.
Read more...
http://www.worldpharmanews.com/amgen/2070-cancer-support-community-launches-national-program-to-assist-patients-with-cancer
 
H1N1 discovery paves way for universal flu vaccine
‎University of British Columbia researchers have found a potential way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations. Each year, seasonal influenza causes serious illnesses in three to five million people and 200,000 to 500,000 deaths.
Read more...
http://www.worldpharmanews.com/research/2069-h1n1-discovery-paves-way-for-universal-flu-vaccine
 
Some HDL, or 'good' cholesterol, may not protect against heart disease
‎A new study by Harvard School of Public Health (HSPH) researchers has found that a subclass of high-density lipoprotein (HDL) cholesterol, the so-called "good" cholesterol, may not protect against coronary heart disease (CHD) and in fact may be harmful.
Read more...
http://www.worldpharmanews.com/research/2068-some-hdl-or-good-cholesterol-may-not-protect-against-heart-disease
 
Roche reports positive study of RoACTEMRA given by subcutaneous injection
‎Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) 162mg weekly compared to 8 mg/kg RoACTEMRA intravenous (IV) formulation every 4 weeks.
Read more...
http://www.worldpharmanews.com/roche/2067-roche-reports-positive-study-of-roactemra-given-by-subcutaneous-injection
 
Abbott to Acquire Action Pharma's Investigational Compound, AP214
‎Abbott (NYSE: ABT) and Action Pharma A/S, a privately owned company, announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma. AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in adjacent indications.
Read more...
http://www.worldpharmanews.com/abbott/2066-abbott-to-acquire-action-pharmas-investigational-compound-ap214
 
Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company
‎Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals. Under the terms of the agreement, Novartis will acquire the business, which is based in Melville, New York, for USD 1.525 billion in an all-cash transaction.
Read more...
http://www.worldpharmanews.com/novartis/2065-sandoz-to-acquire-fougera-pharmaceuticals-becoming-the-number-one-generic-dermatology-medicines-company
 
GlaxoSmithKline and Yale University establish drug discovery collaboration
‎GlaxoSmithKline plc (GSK) and Yale University have established a drug discovery research collaboration to design a potential new class of medicines that degrade disease-causing proteins. The collaboration combines GSK's expertise in medicinal chemistry with Yale's pioneering work on proteolysis targeting chimeric molecules or PROTACs.
Read more...
http://www.worldpharmanews.com/gsk/2064-glaxosmithkline-and-yale-university-establish-drug-discovery-collaboration
 
Potential to revive abandoned cancer drug by nanoparticle drug delivery
Current nanomedicine research has focused on the delivery of established and novel therapeutics. But a UNC team is taking a different approach. They developed nanoparticle carriers to successfully deliver therapeutic doses of a cancer drug that had previously failed clinical development due to pharmacologic challenges.
Read more...
http://www.worldpharmanews.com/research/2063-potential-to-revive-abandoned-cancer-drug-by-nanoparticle-drug-delivery
 
PharmaNews.eu / Latest News
 
 
 
 
 
 
 
Reflection paper on classification of advanced therapies released for public consultation
http://www.pharmanews.eu/ema/1048-reflection-paper-on-classification-of-advanced-therapies-released-for-public-consultation
 
With best regards,
Ruslan David
Administrator/Editor
 
 
PS: Want to place your News, Brand, Service, Product or Event in front of World Pharma News?
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
http://www.worldpharmanews.com/contact-us
 
Reply all
Reply to author
Forward
0 new messages